当前位置: 首页 > 详情页

Expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)

文献详情

资源类型:
Pubmed体系:
作者:
机构: [1]Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center of the Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of the Chinese PLA, Beijing, China [2] Organ Transplantation Center, the Affiliated Hospital of Qingdao University, Shandong, China. [3] Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [4] Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing, China [5] Faculty of Hepato-Pancreato-Biliary Surgery, the Eighth Medical Center of the Chinese PLA General Hospital, Beijing, China [6] Department of Hepatobiliary Surgery, Beijing ChaoYang Hospital, Capital Medical University, Beijing, China [7] Senior Department of Hepatology, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [8] Comprehensive Liver Cancer Center, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [9] Department of General Surgery Center, Beijing Youan Hospital, Capital Medical University, Beijing, China [10] Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China [11] Department of Medical Oncology, Beijing Youan Hospital, Capital Medical University, Beijing, China [12] Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China [13] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Hepatopancreatobiliary Surgery Department I, Peking University Cancer Hospital & Institute, Beijing, China [14] Department of General Surgery, Peking University First Hospital, Beijing, China [15] Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China [16] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Sarcoma Center, Peking University Cancer Hospital & Institute, Beijing, China [17] Department of Hepatobiliary and Pancreatic Surgery, Qinghai Red Cross Hospital, Qinghai, China [18] Department of Interventional Radiology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China [19] Faculty of Hepato-Pancreato-Biliary Surgery, the Sixth Medical Center of the Chinese PLA General Hospital, Beijing, China [20] Department of Radiation Oncology, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China [21] [22] Department of Interventional Therapy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning, China [23] Faculty of Hepato-Pancreato-Biliary Surgery, the Fourth Medical Center of the Chinese PLA General Hospital, Beijing, China [24] Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China [25] Department of Hepatobiliary Surgery, Xijing Hosptial, the Fourth Military Medical University, Shanxi, China [26] Department of Medical Oncology, Peking University International Hospital, Beijing, China [27] Department of Hepatobiliary Surgery, Peking University International Hospital, Beijing, China [28] Department of General Surgery, Shengjing Hospital of China Medical University, Liaoning, China [29] Department of Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang, China [30] Department of Gastroenterology, People's Hospital of Chongqing Hechuan, Chongqing, China [31] Department of Hepatobiliary Surgery, Weifang People's Hospital, Shandong, China [32] Hepatobiliary Surgery Center, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [33] Chinese Journal of Hepatobiliary Surgery, Beijing, China [34] Department of Hepatobiliary and Pancreatic Surgery, the Affiliated Hospital of Qingdao University, Shandong China [35] Department of Hepatology and Gastroenterology, Beijing Youan Hospital, Capital Medical University, Beijing, China [36] Department of Liver Transplantation Center, Beijing Youan Hospital, Capital Medical University, Beijing, China [37] Department of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fujian, China [38] Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China [39] Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangdong, China [40] Department of Hepatobiliopancreatic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangdong, China [41] Department of Hepatobiliary and Pancreatic Surgery, Peking University First Hospital, Beijing, China [42] Department of General Surgery, Peking University Third Hospital, Beijing, China [43] Department of Hepatobiliary and Pancreatic Surgery, Fujian Provincial Hospital, Fujian, China [44] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Interventional Therapy, Peking University Cancer Hospital & Institute, Beijing, China [45] Department of Medical Oncology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China [46] Department of General Surgery, the First Affiliated Hospital of Dalian Medical University, Liaoning, China [47] Department of Hepatobiliary Surgery and Organ Transplantation Center, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Anhui, China [48] Department of General Surgery, Beijing Hospital, National Center of Gerontology [49] Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China [50] Zhongshan Hospital, Fudan University, Shanghai, China [51] The Department of Hepatobiliary Surgery, the Second Affiliated Hospital of Hainan Medical University, Hainan, China [52] Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Tianjin, China [53] Department of Pathology, the First Medical Center of the Chinese PLA General Hospital, Beijing, China [54] Department of General Surgery, Beijing Shijingshan Hospital, Beijing, China [55] Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Hubei, China [56] Department of Hepatobiliary Surgery, the Fourth Hospital of Hebei Medical University, Hebei, China [57] Department of Gastroenterology, Beijing Chest Hospital, Capital Medical University, Beijing, China [58] Department of Radiology, the First Hospital of China Medical University, Liaoning, China [59] Department of Liver Surgery, West China Hospital, Sichuan University, Sichuan, China [60] Department of General Surgery, Tangdu Hospital, the Fourth Military Medical University, Shanxi, China [61] Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Guangxi, China [62] Institute of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China [63] Department of Hepatobiliary Surgery, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, China [64] Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Shandong, China [65] Department of Interventional Ultrasound, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [66] Department of Gastrointestinal Oncology, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [67] Department of Immunology and National Center for Biomedicine Analysis, the Fifth Medical Center of the Chinese PLA General Hospital, Beijing, China [68] Department of Transplant Surgery, Qilu Hospital of Shandong University, Shandong, China [69] Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing, China [70] Center of Hepato Pancreato Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangdong, China [71] Department of Oncology and Hematology, the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong, China [72] Department of Hepatobiliary and Pancreatic Surgery, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Henan, China [73] Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai Key Laboratory of Organ Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Zhongshan Hospital, Fudan University, Shanghai, China.
出处:
ISSN:

关键词: hepatocellular carcinoma molecularly targeted therapy hepatectomy immune checkpoint inhibitors conversion therapy

摘要:
Up to half of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage, for which effective treatment options are lacking, resulting in a poor prognosis. Over the past few years, the combination of immune checkpoint inhibitors and anti-angiogenic targeted therapy has proven highly efficacious in treating advanced HCC, significantly extending patients' survival and providing a potential for sequential curative surgery. After sequential curative hepatectomy or liver transplantation following conversion therapy, patients can receive long-term survival benefits. In order to improve the long-term survival rate of the overall population with liver cancer and achieve the goal of a 15% increase in the overall 5-year survival rate outlined in the Healthy China 2030 blueprint, the Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association, Chinese Society of Liver Cancer, and the Liver Study Group of Surgery Committee of Beijing Medical Association organized in-depth discussions among relevant domestic experts in the field. These discussions focused on the latest progress since the release of the Chinese expert consensus on conversion therapy of immune checkpoint inhibitors combined antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2021 Edition) and resulted in a new consensus on the modifications and supplements to related key points. This consensus aims to further guide clinical practice, standardize medical care, and promote the development of the discipline.

语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 4 区 生物学
小类 | 4 区 生物学
最新[2023]版:
大类 | 4 区 生物学
小类 | 4 区 生物学
第一作者:
第一作者机构: [1]Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center of the Chinese PLA General Hospital, Institute of Hepatobiliary Surgery of the Chinese PLA, Beijing, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院